Revealing the secrets of a part

CT inspection in automation technology at Festo.

Novartis stämmer Astra Zeneca-bolag för påstått falska budskap

Novartis stämmer Alexion, Astra Zenecas enhet för sällsynta sjukdomar, som man anklagar för att ha lanserat “en falsk och vilseledande marknadsföringskampanj”.

The New Precise Magazine is Available Now

Download the new issue.

Scientific Solutions

Smartzoom 100 – The New Digital Microscope for Maximum Efficiency

Free webinar July 1, 9:00-9:45 AM CEST and 5:00-5:45 PM CEST.

Pneumatics Makes a Technological Leap with Piezo

The first high-precision proportional valve terminal VTEP opens up new application areas

New cell therapy raises hope for curing type 1 diabetes – "Never succeeded before"

For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified insulin-producing cells that do not require...

Studie: Protein i urinen en biomarkör för demensrisk

Höga nivåer av proteinet albumin i urinen indikerar en ökad risk för att utveckla demens, enligt en stor studie från Karolinska institutet, KI.

Abera meddelar positiva data för influensavaccin

Vaccin- och bioteknikbolaget Abera Bioscience meddelar att den första in vivo-studien med den nya nasala vaccinkandidaten mot influensa visat lovande resultat.

Medivir i nytt avtal om cancerläkemedel i gelform

Svenska Medivir har ingått ett licenssamarbete med kanadensiska Biossil för fortsatt utveckling av Remetinostat, ett gelbaserat läkemedel som utvecklats för beh...

High-tech companies are increasingly focusing on health

Tech companies have been taking an interest in healthcare for many years, and this interest seems to be increasing. “It’s not a sudden shift in trend, it’s more...

ZEISS introduces the new Smartzoom 100

The future of digital microscopy for efficient optical inspections.

MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.

EasiHeat - en komplett och kompakt värmeväxlarlösning

Spirax EasiHeat™ är en komplett och kompakt lösning för uppvärmning av vatten med ånga.

Merck KGaA acquires American company in €3.0 billion deal

Germany’s Merck is completing the acquisition of Springwork Therapeutics for 3 billion euros.

Recipharms AI-satsning får stöd från Gates-stiftelse

Svenska Recipharm får utökad finansiering från Bill & Melinda Gates Foundation för att utveckla AI-drivna tillverkningsteknologier. Syftet är att sänka produkti...

Improving Nano-Structured Surfaces for Implants with Scanning Electron Microscopy

Promimic, a Swedish company specializing in the development and marketing of nano-structured surfaces for implants, heavily relies on scanning electron microscopes.

Advanced workflow automation and scalable image analysis in spatial biology

ZEISS and Concept Life Sciences announce partnership.

AstraZeneca´s Trixeo approved in the UK using propellant with near-zero Global Warming Potential

AstraZeneca has received approval in the United Kingdom for its inhaled respiratory medicine Trixeo Aerosphere with a new propellant that is reported to reduce ...

One System, Three Contrasting Techniques

ZEISS Axioscan 7 clinical - your digital slide scanner for diagnostics and clinical research.

Thumbs down for lecanemab in the EU – “Very surprised”

The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...

Roche’s Genentech terminates licencing deal with Norwegian biotech

Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.

The race between new alzheimer’s drugs Kisunla and Leqembi heats up

Kisunla or Leqembi? The rivalry between Eli Lilly and Bioarctic is intensifying. Where one drug gains approval, the other falls behind. Here's a look at the mar...

Positiva data för vaccin i pulverform – ”Fungerar lika bra”

En ny studie indikerar att ett nytt influensavaccin, som utvecklas av Abera Bioscience i samarbete med Orexo, fungerar både som sprej och pulver.